Our Story

Our mission is to enable access to high quality, affordable,
specialty NGS testing, performed by any NGS laboratory as
clinical grade tests, closer to home, for all patients.

Leadership Team

Randy Pritchard

Chief Executive Officer Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.

Zhaohui Wang, Ph.D.

Co-founder and Chief Scientific Officer Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Previously, she held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Wang received her Ph.D. in Cellular and Molecular Biology from the University of Massachusetts, Amherst.

Rich Shea Headshot

Rick Shea

Chief Financial Officer Rick Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 to July 2020. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Rick served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Rick received an AB from Princeton University and an MBA from the Public Management Program at Boston University.

Dan Harma

Chief Commercial Officer Mr. Dan Harma is the Chief Commercial Officer of Pillar Biosciences. He has more than 30 years of experience in the medical device industry, notably in in-vitro diagnostics, molecular diagnostics, and hematology markets. Prior to joining Pillar Biosciences, he served as Chief Commercial Officer at NeuMoDxTM where he led the commercial team and assisted in transitioning the business from research and development stage to full commercialization. Previously, he held multiple roles at Abbott Laboratories, Inc., in both the Diagnostics and Molecular divisions. His positions included oversight of product marketing, sales leadership, and commercial development. Mr. Harma received his MBA from Loyola University and his BBA in Marketing from the University of Wisconsin-Whitewater.

Mike Crowell

Vice President of Operations Mr. Mike Crowell is VP of Operations for Pillar Biosciences. He has more than 25 years of healthcare experience with 20 plus years leading operations for molecular diagnostic companies. He has developed deep experience helping regulated life sciences organizations achieve sustained competitive advantage and growth through enhanced customer experience, operational efficiency, organizational agility, and continuous process improvement. He has held positions of increasing responsibilities, including Sr. Director of Operations, Supply Chain and OpEx with Illumina Inc., and Sr. Director Global Supply Chain with Tethys Bioscience and Monogram Biosciences (LabCorp) respectively. Mr. Crowell received a master’s degree from National University of Singapore in International Business as well as an MBA from UCLA Anderson School of Management.

Qiang Wang, PhD

General Manager, China Dr. Qiang Wang is General Manager for Zhengu Biotech (Pillar China). Dr. Wang has more than 15 years of leadership experience in the biotech and pharmaceutical industries. He has held positions as General Manager of Shanghai Fosun Pharmaceutical Co. and Deputy General Manager of Shanghai Sea rainbow medicine e-commerce Co., Ltd. Dr. Wang received his Ph.D. in Health Economics from Fudan University and an MBA from Shanghai Jiaotong University.

Christa Adkins

General Counsel Ms. Christa Adkins is General Counsel at Pillar Biosciences. She has more than 20 years of experience as internal counsel to multi-national corporations and early-stage companies. Prior to joining Pillar Biosciences, she served as General Counsel, Corporate Secretary, and Member of the Equity Incentive Plan Committee at Vibenomics, Inc. Previously, she spent more than 10 years at Roche Diagnostic Corporation, as Commercial Lawyer and Director of Ethics and Compliance. She also has extensive nonprofit board leadership experience and is currently the Chair of the Board of Trustees for the Nature Conservancy of Indiana, Trustee for the Indianapolis Zoological Society, and Trustee for the Orchard School. Ms. Adkins holds a JD from Indiana University Robert H. McKinney School of Law and a BS in Economics from Purdue University.

Board of Directors

Dr. Gang Song is the founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp® technology. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. Previously, Dr. Song was a Technical Lead at Integrated Genetics, LabCorp (previously Genzyme Genetics), and prior to that, was a Project Lead at IQuum before its acquisition by Roche Molecular Diagnostics. Dr. Song completed his postdoctoral training in Timothy Springer’s lab at Harvard Medical School and received his Ph.D. from Shanghai Medical College of Fudan University, China.

Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.

Robert Forrester has more than two decades of experience serving as chief executive officer or chief financial officer for both private and public biopharma companies. Prior to joining EQRx, Robert was CEO of Verastem Oncology, Chief Operating Officer or Chief Financial Officer at Forma Therapeutics, CombinatoRx (now ZLCS), and Coley Pharmaceutical Group. Robert also served as Managing Director of the Proprietary Investment Group at MeesPierson. He holds a LL.B. from Bristol University.

Simone Song is the founder and senior partner of ORI Capital. She serves as investor director on a number of companies that ORI Healthcare Fund has invested, including AffyImmune, Cold Genesys, Enable Injections, Kymab, Pillar Biosciences, TriSalus Medical, etc. Simone was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone received a BA in Economics from Fudan University in China and an MA in Economics from Claremont Graduate School.

Elaine is a Director of ORI Capital. She leads the deal initiation, due diligence and execution process as well as the post investment portfolio management activities. Elaine was a Vice President of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was Assistant Manager with the Audit & Assurance Division of KPMG China. Elaine received a BA in English Literature from Tsinghua University and an MBA from UCLA Anderson School of Management. She is a licensed CPA by the Chinese Institute of Certified Public Accountants.

Dr. Eric Lai has more than 20 years’ experience in drug and IVD molecular diagnostic development. Dr. Lai was SVP of Genomic Medicine at Takeda, and before that he was SVP of Research & Development at Gen-Probe (now part of Hologic) and VP of Pharmacogenetics at GlaxoSmithKline. Dr. Lai received his Ph.D. from Columbia University and did his post-doctoral training in Dr. Hood’s lab at CalTech in the early days of the Human Genome Project. Dr. Lai focused on clinical applications of Pharmacogenomics in drug development and safety. In 2002, he discovered the association of HLA5701 to Abacavir hypersensitivity. This discovery is frequently cited in FDA guidance as one of the most important demonstrations of precision medicine.

Scientific Advisory Board

Siraj Ali, MD, Ph.D.

VP of Clinical Development, EQRx Inc.

Cheng-Zhong Zhang, Ph.D.

Co-Founder, Pillar Biosciences Assistant Professor, Harvard Medical School

Marcia Eisenberg, Ph.D.

Chief Scientific Officer and Sr. VP, LabCorp

Timothy Springer, Ph.D.

Professor, Harvard Medical School

Paul M. Waring, MBBS, Ph.D., FRCPA, FRCPath, FHGSA, FFSc(RCPA)

Executive Director, Translational Pathology, AstraZeneca

Investors

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top